Lymphoma in Patients with Inflammatory Bowel Disease : A Multicentre Collaborative Study Between GETAID and LYSA
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com..
BACKGROUND: Inflammatory bowel disease [IBD] is associated with an increased risk of developing lymphoma. Although recent data have clarified the epidemiology of lymphoma in IBD patients, the clinical and pathological characteristics of lymphoma in IBD remain poorly known.
METHODS: Patients with IBD and lymphoma were retrospectively identified in the framework of a national collaborative study including the Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] and the Lymphoma Study Association [LYSA]. We characterized clinical and prognostic features for the three most frequent lymphoma subtypes occurring in IBD. We performed a multicentre case-control study. Controls [lymphoma de novo] were matched [5:1] to cases on gender, age at diagnosis, lymphoma subtype, year of diagnosis, and IPI/FLIPI indexes. Overall survival and progression-free survival were compared between cases and controls.
RESULTS: In total, 133 IBD patients with lymphoma were included [males = 62.4%, median age at lymphoma diagnosis = 49 years in males; 42 years in females]. Most had Crohn's disease [73.7%] and were exposed to thiopurines [59.4%]. The most frequent lymphoma subtypes were diffuse large B cell lymphoma [DLBCL, 45.1%], Hodgkin lymphoma [HL, 18.8%], and follicular lymphoma [FL, 10.5%]. When matched with 365 controls, prognosis was improved in IBD patients with DLBCL compared to controls [p = 0.0064, hazard ratio = 0.36] or similar [HL and FL].
CONCLUSIONS: Lymphomas occurring in IBD patients do not seem to have a worse outcome than in patients without IBD. Due to the rarity of this situation, such patients should be managed in expert centres.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 18(2024), 4 vom: 23. Apr., Seite 533-539 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muller, Marie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crohn’s disease |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 23.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjad177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363430938 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363430938 | ||
| 003 | DE-627 | ||
| 005 | 20240424231847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjad177 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM363430938 | ||
| 035 | |a (NLM)37850555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muller, Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lymphoma in Patients with Inflammatory Bowel Disease |b A Multicentre Collaborative Study Between GETAID and LYSA |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Inflammatory bowel disease [IBD] is associated with an increased risk of developing lymphoma. Although recent data have clarified the epidemiology of lymphoma in IBD patients, the clinical and pathological characteristics of lymphoma in IBD remain poorly known | ||
| 520 | |a METHODS: Patients with IBD and lymphoma were retrospectively identified in the framework of a national collaborative study including the Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] and the Lymphoma Study Association [LYSA]. We characterized clinical and prognostic features for the three most frequent lymphoma subtypes occurring in IBD. We performed a multicentre case-control study. Controls [lymphoma de novo] were matched [5:1] to cases on gender, age at diagnosis, lymphoma subtype, year of diagnosis, and IPI/FLIPI indexes. Overall survival and progression-free survival were compared between cases and controls | ||
| 520 | |a RESULTS: In total, 133 IBD patients with lymphoma were included [males = 62.4%, median age at lymphoma diagnosis = 49 years in males; 42 years in females]. Most had Crohn's disease [73.7%] and were exposed to thiopurines [59.4%]. The most frequent lymphoma subtypes were diffuse large B cell lymphoma [DLBCL, 45.1%], Hodgkin lymphoma [HL, 18.8%], and follicular lymphoma [FL, 10.5%]. When matched with 365 controls, prognosis was improved in IBD patients with DLBCL compared to controls [p = 0.0064, hazard ratio = 0.36] or similar [HL and FL] | ||
| 520 | |a CONCLUSIONS: Lymphomas occurring in IBD patients do not seem to have a worse outcome than in patients without IBD. Due to the rarity of this situation, such patients should be managed in expert centres | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a ulcerative colitis | |
| 700 | 1 | |a Broséus, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Guilloteau, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a Wasse, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Thiéblemont, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Nancey, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Cadiot, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Amiot, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Laharie, David |e verfasserin |4 aut | |
| 700 | 1 | |a Vieujean, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bouhnik, Yoram |e verfasserin |4 aut | |
| 700 | 1 | |a Martineau, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Michiels, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Hebuterne, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Savoye, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Franchimont, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Seksik, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Beaugerie, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Maynadié, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Feugier, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 18(2024), 4 vom: 23. Apr., Seite 533-539 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:4 |g day:23 |g month:04 |g pages:533-539 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjad177 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 4 |b 23 |c 04 |h 533-539 | ||